Switch theme
Sign up to access all valuation multiples
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
2014
163
LTM Revenue $91.2M
LTM EBITDA -$176M
$2.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arcellx has a last 12-month revenue (LTM) of $91.2M and a last 12-month EBITDA of -$176M.
In the most recent fiscal year, Arcellx achieved revenue of $108M and an EBITDA of -$99.1M.
Arcellx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arcellx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $91.2M | XXX | $108M | XXX | XXX | XXX |
| Gross Profit | $91.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$176M | XXX | -$99.1M | XXX | XXX | XXX |
| EBITDA Margin | -193% | XXX | -92% | XXX | XXX | XXX |
| EBIT | -$177M | XXX | -$138M | XXX | XXX | XXX |
| EBIT Margin | -194% | XXX | -127% | XXX | XXX | XXX |
| Net Profit | -$151M | XXX | -$107M | XXX | XXX | XXX |
| Net Margin | -166% | XXX | -99% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Arcellx's stock price is $62.
Arcellx has current market cap of $3.4B, and EV of $2.9B.
See Arcellx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.9B | $3.4B | XXX | XXX | XXX | XXX | $-2.78 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Arcellx has market cap of $3.4B and EV of $2.9B.
Arcellx's trades at 27.1x EV/Revenue multiple, and -29.6x EV/EBITDA.
Equity research analysts estimate Arcellx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arcellx has a P/E ratio of -22.6x.
See valuation multiples for Arcellx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV (current) | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| EV/Revenue | 32.1x | XXX | 27.1x | XXX | XXX | XXX |
| EV/EBITDA | -16.6x | XXX | -29.6x | XXX | XXX | XXX |
| EV/EBIT | -16.5x | XXX | -21.3x | XXX | XXX | XXX |
| EV/Gross Profit | 32.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -22.6x | XXX | -31.9x | XXX | XXX | XXX |
| EV/FCF | -25.6x | XXX | -30.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArcellx's last 12 month revenue growth is 11%
Arcellx's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.5M for the same period.
Arcellx's rule of 40 is -47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arcellx's rule of X is -166% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Arcellx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | -193% | XXX | -92% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -47% | XXX | -81% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -166% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 146% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 227% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arcellx acquired XXX companies to date.
Last acquisition by Arcellx was XXXXXXXX, XXXXX XXXXX XXXXXX . Arcellx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Arcellx founded? | Arcellx was founded in 2014. |
| Where is Arcellx headquartered? | Arcellx is headquartered in United States of America. |
| How many employees does Arcellx have? | As of today, Arcellx has 163 employees. |
| Who is the CEO of Arcellx? | Arcellx's CEO is Mr. Rami Elghandour. |
| Is Arcellx publicy listed? | Yes, Arcellx is a public company listed on NAS. |
| What is the stock symbol of Arcellx? | Arcellx trades under ACLX ticker. |
| When did Arcellx go public? | Arcellx went public in 2022. |
| Who are competitors of Arcellx? | Similar companies to Arcellx include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arcellx? | Arcellx's current market cap is $3.4B |
| What is the current revenue of Arcellx? | Arcellx's last 12 months revenue is $91.2M. |
| What is the current revenue growth of Arcellx? | Arcellx revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Arcellx? | Current revenue multiple of Arcellx is 32.1x. |
| Is Arcellx profitable? | Yes, Arcellx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Arcellx? | Arcellx's last 12 months EBITDA is -$176M. |
| What is Arcellx's EBITDA margin? | Arcellx's last 12 months EBITDA margin is -193%. |
| What is the current EV/EBITDA multiple of Arcellx? | Current EBITDA multiple of Arcellx is -16.6x. |
| What is the current FCF of Arcellx? | Arcellx's last 12 months FCF is -$114M. |
| What is Arcellx's FCF margin? | Arcellx's last 12 months FCF margin is -125%. |
| What is the current EV/FCF multiple of Arcellx? | Current FCF multiple of Arcellx is -25.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
